Clinical Trial Detail

NCT ID NCT03802747
Title Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Colorado, Denver
Indications

colorectal cancer

Therapies

Durvalumab + Tremelimumab

Durvalumab

Age Groups: senior adult

No variant requirements are available.